Giving patients with a common form of breast cancer an immunotherapy drug before surgery appears to boost outcomes, a n ...

Ovarian Cancer Targeted Medication: PARP Inhibitors, Anti-Angiogenic Drugs, Immunotherapy, and More Ovarian cancer is the malignancy with the highest rate of death from tumors of the female ...

The intersection of radiopharmaceuticals and nanotechnology has propelled the field of medicine forward, particularly concerning targeted cancer therapies.

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...